Skip to main
ACON

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion Inc has demonstrated a robust growth trajectory, with Q3 revenue increasing by 31% year-over-year to $18,942, primarily driven by an 89% rise in Nociscan report volumes, indicating strong market demand for its innovative healthcare technology. The company is also expanding its presence through significant commercial agreements with well-established medical institutions, enhancing its market penetration and potential for revenue growth. Furthermore, the positive impact of favorable coverage decisions from private health insurers in the UK suggests that Nociscan adoption is accelerating, contributing to a strong outlook for future performance.

Bears say

Aclarion Inc faces significant challenges stemming from slower than expected traction with both surgeons and payers, which undermines the company's ability to grow its revenue from the Nociscan platform. Additionally, ongoing adjustments to FY25 earnings per share estimates indicate a troubling increase in operating expenses, with projections being downgraded to as low as $(15.13). The company's financial outlook is further complicated by balance sheet and liquidity risks, as well as uncertainties surrounding regulatory approvals, commercialization efforts, and reimbursement adequacy.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.